Skip to main content
OpenTrials

Clinical trial condition

Recurrent Non-Hodgkin Lymphoma

Explore clinical trials studying Recurrent Non-Hodgkin Lymphoma. Study availability and eligibility vary by location and protocol.

41 public trials 4 recruiting studies
Refine in advanced search Browse all conditions

Recurrent Non-Hodgkin Lymphoma trial results

Completed

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

NCT01381692

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +38 more
Locations
  • Presbyterian - Saint Lukes Medical Center - Health One Denver, Colorado, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • Mayo Clinic in Rochester Rochester, Minnesota, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
View Trial Details
Completed

Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

NCT01822509

Conditions
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Blood Protein Disorders, Bone Marrow Diseases, +44 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • City of Hope South Pasadena South Pasadena, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
View all 13 locations
View Trial Details
Completed

Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant

NCT00068718

Conditions
Blast Crisis, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blood Protein Disorders, +38 more
Locations
  • VA Puget Sound Health Care System Seattle, Washington, United States
  • Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States
  • Universitaet Leipzig Leipzig, Germany
  • University of Torino Torino, Italy
View Trial Details
Completed

Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma

NCT00005803

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +33 more
Locations
  • Huntsman Cancer Institute/University of Utah Salt Lake City, Utah, United States
  • LDS Hospital Salt Lake City, Utah, United States
  • VA Puget Sound Health Care System Seattle, Washington, United States
  • Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States
View Trial Details
Completed

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

NCT01527045

Conditions
Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Blood Protein Disorders, +57 more
Locations
  • Presbyterian - Saint Lukes Medical Center - Health One Denver, Colorado, United States
  • Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
View Trial Details
Completed

Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

NCT01076543

Conditions
AIDS-Related Hodgkin Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +27 more
Locations
  • Northwestern University Chicago, Illinois, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • Decatur Memorial Hospital Decatur, Illinois, United States
  • Ingalls Memorial Hospital Harvey, Illinois, United States
View Trial Details
Completed

Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma

NCT00703664

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Moffitt Cancer Center Tampa, Florida, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • Northwestern University Chicago, Illinois, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
View Trial Details
Completed

Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma

NCT01567709

Conditions
Adult B Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia, Anaplastic Large Cell Lymphoma, +84 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Penn State Milton S Hershey Medical Center Hershey, Pennsylvania, United States
View Trial Details

Related conditions